So where do we currently stand with regard to the evidence on EVAR, and how might we move forward? As might be expected, there are clear early benefits with lower procedure-related mortality following EVAR. The initial results of the EVAR 1 trial reported a significant reduction in 30-day mortality from 4.7% for open repair to 1.7% for EVAR, 3 and this was consistent with the mortality benefit seen in the DREAM trial 4 and with the collected non-randomised comparisons in the systematic review. 5 Meta-analysis from the review suggests a significant benefit, with an